Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

NYU Clinical Cancer Center, New York

Memorial Sloan Kettering Nassau, New York

St. Luke's Hospital, Easton

Duke University Medical Center, Durham

GHS Cancer Institute, Greenville

Hopital Larrey, Toulouse

Orlando Health Inc, Orlando

University Of Louisville Medical Center, Inc., Dba, Louisville

The Christ Hospital, Cincinnati

University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr, Madison

Washington University School Of Medicine, St Louis

Huntsman Cancer Institute, Salt Lake City

University Of New Mexico Cancer Center, Albuquerque

Comprehensive Cancer Centers Of Nevada, Las Vegas

San Francisco Oncology Associates, San Francisco

Institut Gustave Roussy, Villejuif

Oregon Health & Science University, Portland

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

Dartmouth-Hitchcock Medical Center, Lebanon